- Recordati’s revenue for the first half of 2024 reached EU1.19 billion.
- This marks a 14% increase compared to the same period last year, which was EU1.04 billion.
- Operating income for the company is EU338.5 million.
- The company’s EBITDA is EU452.9 million, reflecting a 12% year-over-year growth.
- Adjusted net income stands at EU301.0 million, showing a 4.7% increase from the previous year.
- Current analyst recommendations for Recordati include 5 buy ratings, 6 hold ratings, and 1 sell rating.
A look at Recordati SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Recordati SpA, a pharmaceutical company, has a mixed outlook based on Smartkarma Smart Scores. While it shows strength in momentum with a score of 4, indicating positive market performance, other factors such as value and dividend fall below with scores of 2 and 3 respectively. The company’s growth and resilience also hold steady with scores of 3 each. Overall, although momentum is high, caution is advised in considering the company’s investment potential due to lower scores in other key areas.
Recordati SpA focuses on manufacturing pharmaceuticals and has a global presence in selling prescription and non-prescription drugs, therapeutic products, and rare disease treatments. With varying scores across different factors, investors may need to closely monitor how the company navigates its financial performance and growth in the long term to make informed investment decisions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
